Trial Profile
A Comparison of the Immunogenicity and Descriptive Safety of a Live Attenuated Herpes Zoster Vaccine and the Glaxo Smith Kline (GSK) Herpes Zoster Recombinant HZ/su Candidate Vaccine in 50-59 Year Old and 70-85 Year Old Vaccine Recipients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs GSK 137173A (Primary) ; Varicella zoster virus vaccine live
- Indications Herpes zoster; Varicella zoster virus infections
- Focus Pharmacodynamics
- 07 Jul 2020 Status changed from active, no longer recruiting to completed.
- 13 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Mar 2020.
- 22 Sep 2018 Results published in the Journal of Infectious Diseases